Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trodelvy in HR+/HER2- metastatic breast cancer
NCT04639986Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Nov 2020
- Primary completion
- Dec 2026
- Countries
- 3
01
Overview
A Phase 3 trial of sacituzumab govitecan in breast cancer, Hormone-Receptor-Positive Breast Cancer, sponsored by Gilead Sciences. Started Nov 2020; status: active, not recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
breast cancerHormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT04639986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04639986.